Prognostic impact of CD38 expression in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma transformation

Leuk Lymphoma. 2022 Jun;63(6):1484-1487. doi: 10.1080/10428194.2021.2024820. Epub 2022 Jan 19.

Authors

Fumiya Wada^{1

2}, Yoshimitsu Shimomura¹, Kimimori Kamijo¹, Daisuke Yamashita³, Aya Ohno⁴, Mayuko Himeno⁴, Hayato Maruoka⁴, Shigeo Hara³, Takayuki Ishikawa¹

Affiliations

¹ Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
² Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
³ Department of Pathology, Kobe City Medical Center General Hospital, Kobe, Japan.
⁴ Department of Clinical Laboratory, Kobe City Medical Center General Hospital, Kobe, Japan.

PMID: 35045767
DOI: 10.1080/10428194.2021.2024820

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Humans
Lymphoma, Follicular* / pathology
Lymphoma, Large B-Cell, Diffuse* / diagnosis
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Lymphoma, Large B-Cell, Diffuse* / genetics
Lymphoma, Non-Hodgkin* / drug therapy
Neoplasm Recurrence, Local / drug therapy
Prognosis